Christine Baudelet

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations

Medicine, Immunology, Oncology +17

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto et al. · The Lancet · 2021 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi‐Long Wu, Shun Lü, Ying Cheng et al. · Journal of Thoracic Oncology · 2019 · 358 citations

Medicine, Oncology, Pharmacology +17

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

David R. Spigel, David Vicente, Tudor–Eliade Ciuleanu et al. · Annals of Oncology · 2021 · 271 citations · Full text

Medicine, Oncology, Pharmacology +17